SSAT SSAT
 
 
Abstracts Only
SSAT residents Corner
Find SSAT on Facebook SSAT YouTube Channel Follow SSAT on Twitter
SSAT
 
2008 Annual Meeting Posters


Is Adjuvant Therapy Indicated After Pancreatectomy for Adenocarcinoma?
Jonathan M. Hernandez*, Daniel Molloy, Jennifer C. Cooper, Carl B. Bowers, Sarah Cowgill, Steven B. Goldin, Alexander S. Rosemurgy
Surgery, University of South Florida and Tampa General Hospital, Tampa, FL

Introduction: Resection is the only hope of cure for patients with pancreatic cancer, though 5-year survival after resection remains dismal. With hope of improving survival, application of adjuvant therapy is intuitively rational. However, adjuvant therapy is applied to a minority of patients after pancreatectomy. The rationale of adjuvant therapy is disconnected from its application. This study was undertaken to assess the data supporting adjuvant therapy following pancreatectomy for adenocarcinoma.
Methods: The National Library of Medicine and the National Institutes of Health were searched for trials of adjuvant therapy after pancreatectomy for adenocarcinoma published since 1980. This search identified 191 trials; 10 were observation-controlled prospective randomized trials. Each trial was graded on its level of data utilizing a National Cancer Institute scale (best score of 1iA to worst score of 3iiiDiii). Methodological deficiencies, including inclusion of other cancers, excluded 7 trials from further review. Meta-analysis was applied to 3 observation-controlled prospective randomized trials of adjuvant therapy. Data collected from the trials included therapies utilized, median survival, 1-year, 2-year, and 5-year survival, and differences in survival by survival curve analysis (Table).Meta-analysis attests that there was not a significant advantage to adjuvant therapy during the first two years after resection, but that a survival advantage did become apparent by five years after resection (odds ratio=2.291, 1.002-5.246, 95% CI).
Results: See Table
Conclusions: There are few observation-controlled prospective randomized trials of adjuvant therapy following pancreatectomy for adenocarcinoma and very few withstand scrutiny. Though very few in numbers, together these trials assert that adjuvant therapy after pancreatectomy for adenocarcinoma improves long-term survival and should be applied. All patients undergoing pancreatectomy for adenocarcinoma should be considered for adjuvant therapy.

Author Therapy Grade # Patients Median Survival (months) 1-Year Survival 2-Year Survival 5-Year Survival Survival Curve Difference
GITSG5FU/XBRT→5FU 1iiA 21 2063% 42%19% p=.03
GITSG observation 22 11 49% 15% 8%
Klinkenbijl 5 FU/XBRT 1iiA 60 17.1 68% 37% 20% p=.10
Klinkenbijl observation 54 12.6 54% 23% 10%
Oettle Gemcitabine 1iiD 179 22.1 72.5% 48% 23% p=.06
Oettle observation 175 20.2 72.5% 42% 12%

Meta-analysis attests that there was not a significant advantage to adjuvant therapy during the first two years after resection, but that a survival advantage did become apparent by five years after resection (odds ratio=2.291, 1.002-5.246, 95% CI).


 

 
Home | Contact SSAT